Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Results in mice suggest that combining drugs such as bevacizumab with chimeric antigen receptor–T cell therapy may benefit patients with glioblastoma.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Results in mice suggest that combining drugs such as bevacizumab with chimeric antigen receptor–T cell therapy may benefit patients with glioblastoma.
Losartan may augment the benefits of other anti-cancer therapies by reducing tumor invasion and immunosuppression.
By developing a new computational tool, researchers have identified a potential target for anti-cancer therapies that could simultaneously deplete tumors of energy and boost the body’s immune response against them.
A new college grad diagnosed with adrenocortical carcinoma, Erin shares more about working and living with cancer as a young adult. Read her patient story.
Taking losartan might allow patients with brain cancer to continue receiving immune checkpoint inhibitors without experiencing the medications’ potentially deadly side effect.
The team's findings sugggest that these data registries do not reflect the true landscape of cancer patients in the US.
Bench-to-bedside research led from preclinical experiments to a durable response among patients with a difficult-to-treat form of colorectal cancer.
In U.S. patients who underwent major cancer operations, the incidence of suicide was significantly higher than the general population.
Using information from a single low-dose chest computed tomography scan, ‘Sybil’ accurately predicted individuals’ lung cancer risk for one to six years in the future, pointing a way toward personalized screening.
Silencing the gene may help overcome resistance to cancer immunotherapy.
An integral part of one of the world’s most distinguished academic medical centers, Mass General Cancer Center is among the leading cancer care providers in the United States.